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Background:  Over the last 50 years, clinical trials of novel interventions for acute heart failure (AHF) have, with few exceptions, been 
neutral or shown harm. Biomarker profiles might identify subsets of patients that respond.
methods:  We studied the effect of rolofylline on 180 day mortality across 24 clinical characteristics and 48 plasma biomarkers (e.g. 
inflammation, cardiomyocyte stretch, remodelling, angiogenesis, renal function) in 1,963 acute heart failure patients using forest plot 
and Subpopulation Treatment Effect Pattern Plot (STEPP) analysis. A simple point score was derived based on the Cox regression 
β-coefficients of biomarkers with treatment interaction, dichotomizing each biomarker at the STEPP determined threshold.
results:  Overall, rolofylline had no effect on 180 day mortality (HR 1.03, 95% CI 0.82-1.28, p=0.808). We found no treatment interactions 
with clinical characteristics. The point score model included TNF-R1α, ST2, WAP Four-Disulfide Core Domain Protein HE4 (WAP-4C ) and 
total cholesterol. In patients with a maximum score of 4 points, those with increased TNF-R1α, ST-2, WAP-4C and low total cholesterol, 
treatment with rolofylline was beneficial (HR 0.61, 95% CI 0.40-0.92, p=0.019), while in patients with score 0, treatment with rolofylline was 
harmful (HR 5.52, 95% CI 1.68-18.13, p=0.005; treatment by score interaction p < 0.001).
conclusion:  A multi-biomarker approach can be used to distinguish responders from non-responders in acute heart failure.
Table: Hazard ratios for rolofylline on 180 day mortality across different subgroups 
Total points Hazard Ratio 95% Confidence Interval P-value
0 5.52 1.68-18.13 0.005
1 1.35 0.76-2.40 0.306
2 0.74 0.44-1.24 0.249
3 1.14 0.67-1.94 0.639
4 0.61 0.40-0.92 0.019
